AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06343883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - high pressure
Description: low-intensity focused ultrasound applied to the S1.
Study NCT05971888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food system and demand generation
Description: GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
Study NCT05032599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CART
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
Study NCT06032598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry extract 1
Description: The study foresees the intake of 1 capsule per day during 84 days
Study NCT06032598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry extract 2
Description: The study foresees the intake of 1 capsule per day during 84 days
Study NCT06032598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 1 capsule per day during 84 days
Study NCT06531473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HoLEP
Description: Patients will be randomized to one of the laser energy groups day of surgery.
Study NCT05017948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk score based intervention
Description: Targeted interventions based off of risk score software
Study NCT05181631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biobanking
Description: Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL.
Study NCT03654079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation
Description: Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
Study NCT05100017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methocarbamol
Description: Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
Study NCT05100017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
Study NCT05180773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
Study NCT05180773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
Study NCT05180773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Guideline Directed Medical Therapy for Heart Failure (GDMT)
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
Study NCT05180773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Directed Medical Therapy for Heart Failure (GDMT)
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
Study NCT05180773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guideline Directed Medical Therapy for Heart Failure (GDMT)
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
Study NCT05180773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
Study NCT05180773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Second Placebo
Description: Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
Study NCT04260243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Myofascial + Respiratory rehabilitation
Description: 6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
Study NCT04260243 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Myofascial + Respiratory rehabilitation
Description: 6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
Study NCT06132581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Description: Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
Study NCT06219707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Study NCT06219707 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Study NCT06298864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-CBT
Description: * Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet.~* Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure to avoided situations, activities and increase in physical activity.~* Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle.
Study NCT06298864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-CL
Description: * Education on ACS, risk factors, its treatments and medication.~* Education and advice promoting healthy habits regarding diet, alcohol and tobacco.~* Education and advice regarding physical activity and the beneficial effects on health.~* Education regarding common emotional reactions following ACS.~* Prevention of relapse and plan forward to maintain a healthy lifestyle.
Study NCT06132581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Description: Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
Study NCT06132581 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Description: Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
Study NCT04946227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg +Paclitaxel 80mg/m2
Description: Pembrolizumab 200mg +Paclitaxel 80mg/m2
Study NCT05144451 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler
Description: Transcranial Doppler-derived parameters; pulsatility index (PI), resistance index (RI), mean flow velocity (Vmean) will be recorded before induction of anesthesia (T1).~After induction, TCD parameters, Hemodynamic variables including heart rate (HR), invasive mean arterial blood pressure (MAP), and central venous pressure (CVP) together with Arterial blood gases (ABG analysis with values of PH, PCO2, PO2, blood oxygen saturation SO2 and bicarbonate HCO3), end-tidal carbon dioxide (ETCO2) and body temperature will be recorded too. Just before skin incision (T2), at the end of anhepatic phase 5 minutes before reperfusion (T3), 5 minutes after reperfusion (T4) and at the end of surgery (T5).~Postoperatively at ICU, TCD parameters, Hemodynamic variables, and ABG will be obtained 24 hours postoperative (T6) and at discharge from ICU (T7).
Study NCT05651958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer
Description: Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
Study NCT05651958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Technique
Description: 15 repeatations of Breathing in morning and evening
Study NCT06363799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4th ventricle compression technique
Description: For the CV4 the mediator's hands assume a specific position: one on top of the other, with the tips of the thumbs joined together in a V shape, positioned approximately on the process spinous between the patient's second and third cervical vertebrae, pointing downwards.
Study NCT06363799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Technique
Description: The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 5 minutes.
Study NCT06363799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing technique
Description: For the diaphragmatic breathing the participant will place one hand on their chest and the other over their abdomen. Both of their hands will be overlapped by the mediator's, so it is easier to feel the correct breathing movements to be performed.
Study NCT05404490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Study NCT05404490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Study NCT04298216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Analysis of Inferior Vena Cavae (IVC)
Description: Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
Study NCT05574504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
Description: Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~* Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~* Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion
Study NCT04298216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Analysis of Inferior Vena Cavae (IVC)
Description: Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
Study NCT06065280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
Study NCT05375136 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention will be administered.
Study NCT06065280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
Study NCT03966651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT with 177Lu-DOTATATE
Description: Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
Study NCT05175482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Education
Description: health belief model based virtual education
Study NCT04763135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment.
Study NCT04763135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment.
Study NCT05334589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prewarming
Description: When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
Study NCT04818632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part A: AZD9833 monotherapy dose escalation.
Study NCT04818632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part B: AZD9833 monotherapy dose expansion
Study NCT04818632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with palbociclib
Description: Part B: AZD9833 with palbociclib dose expansion
Study NCT04818632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with everolimus
Description: Part B: AZD9833 with everolimus dose expansion
Study NCT04640571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin and chenodeoxycholic acid, after metformin and placebo
Description: single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
Study NCT04640571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Description: single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
Study NCT05965648 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)
Description: Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
Study NCT06165627 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric contact lenses
Description: Commercially available soft contact lenses worn as indicated
Study NCT06165627 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A toric contact lenses
Description: Commercially available soft contact lenses) worn as indicated
Study NCT06165627 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated
Study NCT05284539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab
Description: Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
Study NCT04864821 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Targeting CD276 CAR T cells
Description: Targeting CD276 autologous chimeric antigen receptor T cells
Study NCT05753189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: Combination ophthalmic solution of Aceclidine and Brimonidine
Study NCT05753189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Proprietary Vehicle Solution
Study NCT05753189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine Ophthalmic Solution
Description: Aceclidine
Study NCT06286371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Endometriosis Surgery
Description: Laparoscopic Excision of Deep Endometriotic Nodule related to pelvic pain
Study NCT05503927 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study, therefore no intervention is used.
Study NCT05840029 — intervention group
Intervention type: PROCEDURE
Intervention: VIDEO-ASSISTED THORACOSCOPIC SURGERY
Description: A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
Study NCT05578001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic
Description: 1 drop of Pilocarpine 1%